Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cantargia Q1 2024 - Notable Cost Reductions

© Modular Finance, source Nordic Press Releases